文献速递生殖医学

体外受精和胚胎培养基中添加抗氧化剂的前瞻性随机对照试验

A prospective randomized controlled trial of antioxidants in human IVF and embryo culture media.
PubMed 文献 · Hum Reprod · 2025-01-01

单中心前瞻性随机对照优效性试验,2019年1月至2021年11月共随机1482例,比较在配子收集、受精和胚胎培养过程中添加三种抗氧化剂(A3组合)的培养基与对照培养基。新鲜单囊胚移植的临床妊娠率无差异(26.1% vs 22.9%,P>0.05,RR 0.88,95%CI 0.73-1.05);意向性分析中抗氧化剂组受精率显著升高(59.2±26.3% vs 64.5±25.4%,P<0.001)。

要点

  • 新鲜单囊胚移植临床妊娠率抗氧化剂组26.1% vs 对照组22.9%,无显著差异(P>0.05,RR 0.88,95%CI 0.73-1.05)。
  • 意向性分析受精率抗氧化剂组64.5±25.4% vs 对照组59.2±26.3%,显著升高(P<0.001)。
  • ICSI周期亚组受精率抗氧化剂组68.3±24.7% vs 对照组57.9±27.2%,显著升高(P<0.0001)。

核心结论

  • 在IVF和胚胎培养基中添加抗氧化剂未增加新鲜单囊胚移植的临床妊娠率,但意向性分析中受精率显著升高。

研究设计与样本

  • 单中心、前瞻性随机对照优效性试验,2019年1月至2021年11月,共随机1482例,对照组739例,抗氧化剂组743例。

主要发现

  • 每随机患者每周期新鲜胚胎移植临床妊娠率:对照组26.1% vs 抗氧化剂组22.9%(P>0.05,RR 0.88,95%CI 0.73-1.05)。
  • 符合方案人群临床妊娠率:对照组36.7% vs 抗氧化剂组33.2%(P>0.05,RR 0.90,95%CI 0.76-1.07),活产率:对照组32.4% vs 抗氧化剂组29.5%(P>0.05)。
  • 意向性分析受精率:对照组59.2±26.3% vs 抗氧化剂组64.5±25.4%(P<0.001)。
  • 每患者可用囊胚数:对照组2.70±2.59 vs 抗氧化剂组3.09±2.96(P<0.01);囊胚发育率未受影响。
  • ICSI周期亚组受精率:对照组57.9±27.2% vs 抗氧化剂组68.3±24.7%(P<0.0001);受精失败周期数从8.0%降至3.7%(P<0.01);IVF受精周期受精率无影响。

局限性

  • 本研究为单中心研究,抗氧化剂培养基在不同方案诊所中的效果未知。
  • 患者氧化应激可能受炎症、饮食、吸烟状态、抗氧化剂补充消费及其他生活方式因素影响,未纳入分析。
  • 未检验培养过程中更新培养基抗氧化剂的任何潜在效果。
  • 需要进一步研究验证观察到的抗氧化剂对ICSI后受精率的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the addition of three antioxidants to culture media during gamete collection, insemination, and embryo culture increase the clinical pregnancy rate from fresh blastocyst transfers? SUMMARY ANSWER: The clinical pregnancy rate from fresh blastocyst transfers was not increased by the addition of antioxidants to IVF and embryo culture media. WHAT IS KNOWN ALREADY: Addition of antioxidants to media is beneficial in mouse IVF, embryo culture, and cryopreservation. Prospective clinical trials of sibling human oocytes found an improvement in embryo quality and increased pregnancy rates from frozen blastocyst transfers in older patients. STUDY DESIGN, SIZE, DURATION: Single-centre, prospective randomized controlled trial, superiority study comparing media with or without the addition of antioxidants from January 2019 to November 2021. A total of 1482 patients were randomized before egg collection. Patients and their doctors were blinded to the treatment group. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients undergoing IVF/ICSI cycles and intending to undergo a fresh transfer of a single blastocyst were recruited. Exclusion criteria were previous participation in the study, use of cryopreserved oocytes/embryos, artificial oocyte activation, freeze-all cycle, or extraction of sperm from testicular biopsy. Seven hundred thirty-nine patients were randomized to control media and 743 patients to media containing the 'A3' antioxidant combination of acetyl-L-carnitine, α-lipoic acid, and N-acetyl-L-cysteine (treatment group). MAIN RESULTS AND THE ROLE OF CHANCE: The clinical pregnancy rate per randomized patient per cycle from fresh embryo transfer was not different between the control and antioxidant media (26.1% vs 22.9%; P > 0.05; RR 0.88 (95% CI 0.73-1.05)). In the Per Protocol population, which excludes patients with protocol violations or without a fresh transfer due to freeze-all or no embryo available, there was also no difference in between the control and antioxidant media in clinical pregnancy rate (36.7% vs 33.2%; P > 0.05; RR 0.90 (95% CI 0.76-1.07)) and live birth rate (32.4% vs 29.5%, P > 0.05). In the Intention-to-Treat population, antioxidant media produced a significant increase in the fertilization rate from 59.2 ± 26.3% to 64.5 ± 25.4% (P < 0.001) compared to control media. Blastocyst development rate per fertilized oocyte was not affected by antioxidant media, but the higher fertilization rate resulted in more fertilized oocytes per patient and therefore more blastocysts utilized per patient in the antioxidant group compared to the control (2.70 ± 2.59 vs 3.09 ± 2.96, P < 0.01). The increase in fertilization rate was observed in a subgroup analysis of ICSI cycles (57.9 ± 27.2% vs 68.3 ± 24.7%, P < 0.0001), and a decrease in the number of cycles with failed fertilization from 8.0 to 3.7% with antioxidant media (P < 0.01). In contrast, there was no effect of antioxidant media on fertilization rate in cycles with IVF insemination. LIMITATIONS, REASONS FOR CAUTION: This was a single-centre study, so the effects of antioxidant media in clinics with different protocols are unknown. Patient oxidative stress, which may be influenced by inflammation, diet, smoking status, antioxidant supplement consumption, and other lifestyle factors, was not accounted for. Any potential effect of renewing the antioxidants in the media during culture was not examined. WIDER IMPLICATIONS OF THE FINDINGS: Addition of antioxidants to culture media did not affect pregnancy rates from fresh single embryo transfers. An increase in fertilization rate was observed, which resulted in more blastocysts available for transfer and cryopreservation. There was no effect of antioxidants on blastocyst development rate or grade. Further studies are needed to validate the observed effect of antioxidants on fertilization rate following ICSI. STUDY FUNDING/COMPETING INTEREST(S): Culture media and an independent statistician were funded by Vitrolife AB. R.L.K has received travel funding and a speaker's honorarium from Vitrolife. D.K.G. has received research grants from Vitrolife at the University of Melbourne. N.-G.P. has received consulting fees from Vitrolife for work related to the study. All other authors have nothing to declare. TRIAL REGISTRATION NUMBER: ACTRN12618001479291. TRIAL REGISTRATION DATE: 4 September 2018. DATE OF FIRST PATIENT’S ENROLMENT: 28 January 2019.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kelley RL, Lee YSL, Agresta F, et al. A prospective randomized controlled trial of antioxidants in human IVF and embryo culture media. Hum Reprod. 2025. PMID: 40973967. doi:10.1093/humrep/deaf183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。